AI assistant
Rua Bioscience Limited — Earnings Release 2026
Nov 9, 2025
66262_rns_2025-11-10_38bce0ec-b7dc-420a-92b9-94c93f5c066b.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [118 x 68] intentionally omitted <==
10 November 2025
FOR PUBLIC RELEASE
Rua Bioscience sets new quarterly revenue record, underscoring growth
Rua Bioscience is pleased to announce a record revenue result for Q1 FY26 ending September 2025, marking a milestone in the company’s commercial growth. This achievement reflects Rua’s ability to deliver strong sales outcomes across all key markets, including New Zealand, Australia, and Germany.
==> picture [113 x 10] intentionally omitted <==
----- Start of picture text ----- Customer revenue----- End of picture text -----
==> picture [441 x 226] intentionally omitted <==
----- Start of picture text ----- $0.56m$0.47m$0.42m$0.39m$0.22m$0.04mFY24 FY25 FY25 FY25 FY25 FY26Q4 Q1 Q2 Q3 Q4 Q1(unaudited)----- End of picture text -----
The company’s best-ever sales performance highlights both growing demand for Rua’s medicinal cannabis products and the effectiveness of its export-led commercial strategy. It also demonstrates Rua’s ability to scale sales rapidly, provided appropriate funding is in place to support supply and expansion.
Chief Executive Officer Paul Naske said, “This quarter’s results reaffirm that Rua can grow sales effectively across markets. With continued access to funding, we are confident in our ability to maintain this trajectory and expand further.”
Rua’s commercial progress aligns with its founding purpose: to create a high-value, intergenerational company that delivers quality New Zealand-grown medicinal cannabis products to patients at home and abroad. With channels now active in four international markets and a growing product portfolio, Rua is positioned to grow further.
ENDS
The person who authorised this statement:
Paul Naske
Chief Executive Officer [email protected]
+64 21 445154